NCT05200936View on ClinicalTrials.gov

Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

November 6, 2023

Study Completion Date

December 4, 2023

Conditions
ADHDAttention Deficit Disorder
Interventions
DRUG

MM-120

MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.

OTHER

Placebo

A treatment which is designed to have no therapeutic value.

Trial Locations (2)

Unknown

Maastricht University, Maastricht

University Hospital Basel, Basel

All Listed Sponsors
lead

Mind Medicine, Inc.

INDUSTRY

NCT05200936 - Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial | Biotech Hunter | Biotech Hunter